| symbol |
TROV |
|---|
| 会社名 | TrovaGene Inc （トロヴァジ―ン） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Biotechnology: Biological Products (No Diagnostic Substances)
|
|---|
| 業種 |
医療機器_医療用品_ディストリビュ―タ―
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Trovagene Inc. is a clinical-stage precision medicine oncology therapeutics company. The Company’s lead drug candidate PCM-075 is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies such as Zytiga (abiraterone acetate) Beleodaq (belinostat) Quizartinib (AC220) a development stage FLT3 inhibitor and Velcade (bortezomib) in Acute Myeloid Leukemia (AML) metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1 to be administered orally and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway. トロヴァジ―ンは、医療分野で技術開発する米国の会社。疾患検出およびモニタリングで使用するための技術の開発と商業化に注力する。腫瘍学と癌治療管理の分野に焦点を当てる。同社は、病気にかかった細胞死から無細胞DNAとRNAを検出するために、尿ベ―スの分子診断技術を利用。また、尿中の無細胞核酸まわりの知的財産や、尿からの無細胞核酸抽出などを開発。 Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
|
|---|
| 本社所在地 | 11055 Flintkote Avenue Suite B San Diego CA 92121 USA |
|---|
| 代表者氏名 | Thomas H. Adams トーマス・H.アダムス |
|---|
| 代表者役職名 | Chairman of the Board Interim Chief Executive Officer |
|---|
| 電話番号 | +1 858-217-5420 |
|---|
| 設立年月日 | 37347 |
|---|
| 市場名 | NASDAQ Small Cap |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 17人 |
|---|
| url | www.trovagene.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/trov |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -16.88981 |
|---|
| 終値（lastsale） | 0.8716 |
|---|
| 時価総額（marketcap） | 15417534.5468 |
|---|
| 時価総額 | 時価総額（百万ドル） 14.25715 |
|---|
| 売上高 | 売上高（百万ドル） 0.52031 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） -4.26023 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -18.18831 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 TrovaGene Inc revenues increased 8% to $212K. Net loss applicable to common stockholders decreased 37% to $11.3M. Revenues reflect Clinical research services increase from $2K to $31K. Lower net loss reflects Legal and accounting fees decrease of 90% to $288K (expense) Fees licenses and other decrease of 99% to $15K (expense). |
|---|
TROV - トロヴァジ―ン （TrovaGene Inc.） トロヴァジ―ン